Current Report Filing (8-k)
May 11 2017 - 6:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
May 10, 2017
ONCOSEC
MEDICAL INCORPORATED
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
5820
Nancy Ridge Drive
San Diego, California
|
|
92121
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(855) 662-6732
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01.
|
Entry
into a Material Definitive Agreement.
|
On
May 10, 2017, OncoSec Medical Incorporated (“OncoSec”) entered into a clinical trial collaboration and supply agreement
(the “Collaboration and Supply Agreement”) with MSD International GmbH, a subsidiary of Merck (known as MSD outside
the United States and Canada) (“Merck”) to clinically evaluate the combination of OncoSec’s ImmunoPulse®
IL-12 with Merck’s anti PD-1 therapy KEYTRUDA® (pembrolizumab).
Under
the Collaboration and Supply Agreement, OncoSec will sponsor and fund the Phase II multicenter study of ImmunoPulse® IL-12
in combination with KEYTRUDA® in patients with histological diagnosis of melanoma with progressive locally advanced or metastatic
disease defined as Stage III or Stage IV, who are progressing or have progressed on an approved anti-PD-1 therapy (the “PISCES”
study). Merck will be responsible for manufacturing and supplying KEYTRUDA® for the PISCES study.
On
May 10, 2017, OncoSec issued a press release announcing the Collaboration and Supply Agreement. A copy of the press release is
being furnished as Exhibit 99.1 to this Current Report.
The
information in Item 8.01 of this Current Report, including the attached Exhibit 99.1 furnished herewith, is being furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information in Item 8.01 of this Current Report, including
Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference to this Current Report in such a filing.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
Exhibit
|
|
Description
|
99.1
|
|
Press
Release of OncoSec Medical Incorporated dated May 10, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
|
Dated:
May 11, 2017
|
By:
|
/s/
Punit Dhillon
|
|
Name:
|
Punit
Dhillon
|
|
Title:
|
President
& Chief Executive Officer
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024